Rupal Chavda, MD
Rheumatology · Pueblo, CONPI 1760799894
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.3% of the total across 137 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by AbbVie at 28.9% of the total. Reporting peaked in 2023 at $690 and has fallen 76.9% since, to $159 in 2025.
Across 137 payments — averaging $15.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$631
- Amgen$446
- Pfizer$240
- AstraZeneca$144
- Lilly USA, LLC$110
- Novartis$105
- plus $504 from 14 others
What the payments were for
- Food & beverage$2,09796%
- Education$814%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 42 | $631 |
| Amgen(2 entities) | 29 | $446 |
| Pfizer | 22 | $240 |
| AstraZeneca | 5 | $144 |
| Lilly USA, LLC | 6 | $110 |
| Novartis | 6 | $105 |
| Genentech USA, Inc. | 6 | $98 |
| Johnson & Johnson | 3 | $91 |
| GSK | 3 | $48 |
| Merck | 3 | $47 |
| UCB, Inc. | 2 | $40 |
| Mallinckrodt Enterprises LLC | 2 | $30 |
| Actelion Pharmaceuticals US, Inc. | 1 | $23 |
| E.r. Squibb & Sons, L.L.C. | 1 | $23 |
| Hikma Pharmaceuticals USA | 1 | $20 |
| Novo Nordisk | 1 | $18 |
| Bristol Myers Squibb | 1 | $18 |
| Sandoz | 1 | $18 |
| Bioventus LLC | 1 | $16 |
| Sanofi | 1 | $14 |
How this compares
$2,179 in reported general payments places this provider in the 55th percentile of 108 rheumatology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 229 | $1,815,982 |
| RinvoqUpadacitinib | 150 | $1,054,237 |
| Xeljanz XrTofacitinib Citrate | 159 | $952,438 |
| Orencia ClickjectAbatacept | 116 | $886,202 |
| Enbrel SureclickEtanercept | 100 | $795,951 |
| XeljanzTofacitinib Citrate | 69 | $436,257 |
| EnbrelEtanercept | 47 | $409,787 |
| Actemra ActpenTocilizumab | 56 | $273,976 |
| SimponiGolimumab | 28 | $216,540 |
| KevzaraSarilumab | 27 | $199,730 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 14 | $118,453 |
| Cosentyx Sensoready PenSecukinumab | 12 | $103,488 |
| Humira PenAdalimumab | 12 | $85,696 |
| OrenciaAbatacept | 13 | $82,052 |
| OrenciaAbatacept/Maltose | 15 | $66,104 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Restasis, Savella | $631 | $1,100,756189 claims |
| AmgenEnbrel, Prolia | $446 | $469,21981 claims |
| PfizerXeljanz | $240 | $436,25769 claims |
| Johnson & JohnsonSimponi | $91 | $216,54028 claims |
| SanofiKevzara | $14 | $199,73027 claims |
| E.r. Squibb & Sons, L.L.C.Orencia, Orencia | $23 | $148,15628 claims |
| Novo NordiskOzempic | $18 | $37,44217 claims |
| AstraZenecaSymbicort | $144 | $2,74413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 108 rheumatology providers in Colorado.
Other rheumatology in Pueblo
- Patrick TimmsPueblo$15K
- James LevineGreeley$130K
- Aryeh FischerDenver$114K
- Adam BerlinbergDenver$94K
- David TheisColorado Springs$61K
- Rennie McCabeDenver$58K
- Larry MorelandAurora$55K
- Barbara GoldsteinDenver$47K
- Sterling WestAurora$42K
- Ndudi OparaecheEnglewood$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.